{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:42:21Z","timestamp":1790854941951,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.nbd.2006.09.016","type":"journal-article","created":{"date-parts":[[2006,11,28]],"date-time":"2006-11-28T15:32:22Z","timestamp":1164727942000},"page":"297-308","source":"Crossref","is-referenced-by-count":121,"title":["Cardiac dysfunction in the R6\/2 mouse model of Huntington\u2019s disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Michael J.","family":"Mihm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon L.","family":"Schanbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth A.","family":"Altschuld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Anthony","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari R.","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2006.09.016_bib1","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1097\/00001756-200110290-00044","article-title":"Lipoic acid improves survival in transgenic mouse models of Huntington\u2019s disease","volume":"12","author":"Andreassen","year":"2001","journal-title":"NeuroReport"},{"key":"10.1016\/j.nbd.2006.09.016_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2006.09.016_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.410430321","article-title":"Complex I defect in muscle from patients with Huntington\u2019s disease","volume":"43","author":"Arenas","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib4","series-title":"Transgenic mice in the study of polyglutamine repeat expansion diseases","first-page":"699","volume":"8","year":"1998"},{"key":"10.1016\/j.nbd.2006.09.016_bib5","series-title":"Huntington\u2019s Disease","author":"Bates","year":"2002"},{"key":"10.1016\/j.nbd.2006.09.016_bib6","doi-asserted-by":"crossref","first-page":"C1424","DOI":"10.1152\/ajpcell.1996.271.5.C1424","article-title":"Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly","volume":"271","author":"Beckman","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.nbd.2006.09.016_bib7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1091\/mbc.E05-07-0607","article-title":"Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin","volume":"17","author":"Benchoua","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.nbd.2006.09.016_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/0024-3205(95)00055-B","article-title":"Bioenergetic and oxidative stress in neurodegenerative diseases","volume":"56","author":"Bowling","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.nbd.2006.09.016_bib9","series-title":"Heart Disease\u2014A Textbook of Cardiovascular Medicine","year":"2000"},{"key":"10.1016\/j.nbd.2006.09.016_bib10","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/j.1471-4159.1985.tb07192.x","article-title":"Regional mitochondrial respiratory activity in Huntington\u2019s disease brain","volume":"44","author":"Brennan","year":"1985","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2006.09.016_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0301-0082(99)00005-2","article-title":"Replicating Huntington\u2019s disease phenotype in experimental animals","volume":"59","author":"Brouillet","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2006.09.016_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","article-title":"Oxidative damage and metabolic dysfunction in Huntington\u2019s disease: selective vulnerability of the basal ganglia","volume":"41","author":"Browne","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington\u2019s disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol."},{"key":"10.1016\/j.nbd.2006.09.016_bib14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1471-4159.2005.03036.x","article-title":"Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington\u2019s Disease","volume":"93","author":"Brustovetsky","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2006.09.016_bib15","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","article-title":"Characterization of progressive motor deficits in mice transgenic for the human Huntington\u2019s disease mutation","volume":"19","author":"Carter","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib16","unstructured":"CDC\/NCHS, AHA (1988\u201394) In: National Health and Nutrition Examination Study (NHANES III). CDC\/NCHS and the American Heart Association."},{"key":"10.1016\/j.nbd.2006.09.016_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5694\/j.1326-5377.1982.tb132224.x","article-title":"Causes of death in Huntington\u2019s disease","volume":"1","author":"Chiu","year":"1982","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.nbd.2006.09.016_bib18","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","article-title":"Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release","volume":"13","author":"Choo","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2006.09.016_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(97)08360-8","article-title":"Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?","volume":"351","author":"Davies","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2006.09.016_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1098\/rstb.1999.0448","article-title":"From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington\u2019s disease","volume":"354","author":"Davies","year":"1999","journal-title":"Philos. Trans. R. Soc. London, Ser. B Biol. Sci."},{"key":"10.1016\/j.nbd.2006.09.016_bib22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington\u2019s disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2006.09.016_bib23","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.nbd.2006.09.016_bib24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1212\/01.WNL.0000031791.10922.CF","article-title":"Weight loss in early stage of Huntington\u2019s disease","volume":"59","author":"Djousse","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0004.1985.tb00185.x","article-title":"Diabetes mellitus in Huntington disease","volume":"27","author":"Farrer","year":"1985","journal-title":"Clin. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib26","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib27","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib28","doi-asserted-by":"crossref","first-page":"11A","DOI":"10.1016\/S0002-9149(99)80378-6","article-title":"Pathophysiologic aspects of end-stage heart failure","volume":"75","author":"Francis","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.nbd.2006.09.016_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1523\/JNEUROSCI.19-04-01189.1999","article-title":"Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington\u2019s disease","volume":"19","author":"Fusco","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0002-9440(10)62536-9","article-title":"Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice","volume":"159","author":"Gabrielson","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2006.09.016_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.20754","article-title":"Low stability of Huntington muscle mitochondria against Ca2+ in R6\/2 mice","volume":"59","author":"Gizatullina","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","article-title":"Mitochondrial defect in Huntington\u2019s disease caudate nucleus","volume":"39","author":"Gu","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/jnnp.2003.017822","article-title":"Rate and correlates of weight change in Huntington\u2019s disease","volume":"75","author":"Hamilton","year":"2004","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"10.1016\/j.nbd.2006.09.016_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2006.09.016_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","author":"Huntington\u2019s Disease Study Group","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2337\/diabetes.48.3.649","article-title":"Mice transgenic for an expanded CAG repeat in the Huntington\u2019s disease gene develop diabetes","volume":"48","author":"Hurlbert","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.nbd.2006.09.016_bib38","first-page":"VII.58","article-title":"On the hypothesis: cardiac failure is due to decreased energy reserve","volume":"87","author":"Ingwall","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.nbd.2006.09.016_bib39","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1046\/j.1471-4159.2000.0742108.x","article-title":"Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington\u2019s disease mice","volume":"74","author":"Jenkins","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2006.09.016_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1471-4159.2005.03411.x","article-title":"Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington\u2019s disease","volume":"95","author":"Jenkins","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2006.09.016_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1155\/2000\/201406","article-title":"Digital imaging analysis for the study of endotoxin-induced mitochondrial ultrastructure injury","volume":"21","author":"Joshi","year":"2000","journal-title":"Anal. Cell Pathol."},{"key":"10.1016\/j.nbd.2006.09.016_bib42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0733-8651(05)70040-0","article-title":"Is the failing heart energy depleted?","volume":"16","author":"Katz","year":"1998","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.nbd.2006.09.016_bib43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","article-title":"Huntington aggregates may not predict neuronal death in Huntington\u2019s disease","volume":"46","author":"Kuemmerle","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib45","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1212\/WNL.38.5.769","article-title":"Huntington\u2019s disease mortality in the United States","volume":"38","author":"Lanska","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","article-title":"The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies","volume":"2","author":"Li","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.nbd.2006.09.016_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I","article-title":"Abnormal in vivo skeletal muscle energy metabolism in Huntington\u2019s disease and dentatorubropallidoluysian atrophy","volume":"48","author":"Lodi","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib48","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/hmg\/11.17.1911","article-title":"Dysregulation of gene expression in the R6\/2 model of polyglutamine disease: parallel changes in muscle and brain","volume":"11","author":"Luthi-Carter","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2006.09.016_bib50","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1523\/JNEUROSCI.21-22-08772.2001","article-title":"Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington\u2019s disease","volume":"21","author":"Martin-Aparicio","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib51","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1523\/JNEUROSCI.18-01-00156.1998","article-title":"Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington\u2019s disease","volume":"18","author":"Matthews","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib52","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0300-9084(02)00005-6","article-title":"Peroxynitrite-induced inhibition and nitration of cardiac myofibrillar creatine kinase","volume":"84","author":"Mihm","year":"2002","journal-title":"Biochimie"},{"key":"10.1016\/j.nbd.2006.09.016_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00005344-200008000-00007","article-title":"Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage","volume":"36","author":"Mihm","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.nbd.2006.09.016_bib54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0024-3205(01)01141-9","article-title":"Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model","volume":"69","author":"Mihm","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.nbd.2006.09.016_bib55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/01.CIR.104.2.174","article-title":"Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation","volume":"104","author":"Mihm","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.nbd.2006.09.016_bib56","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjp.0704495","article-title":"Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase","volume":"135","author":"Mihm","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2006.09.016_bib57","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.1074\/jbc.M504749200","article-title":"Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin","volume":"280","author":"Milakovic","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2006.09.016_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2003.02009.x","article-title":"Inclusion formation in Huntington\u2019s disease R6\/2 mouse muscle cultures","volume":"87","author":"Orth","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2006.09.016_bib59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","article-title":"Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines","volume":"5","author":"Panov","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0003-9861(02)00585-4","article-title":"In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington\u2019s disease","volume":"410","author":"Panov","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.nbd.2006.09.016_bib61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11010-005-3454-9","article-title":"Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington\u2019s disease individuals","volume":"269","author":"Panov","year":"2005","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.nbd.2006.09.016_bib62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0026-0495(94)90241-0","article-title":"Total-body and myocardial substrate oxidation in congestive heart failure","volume":"43","author":"Paolisso","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.nbd.2006.09.016_bib63","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(72)91092-6","article-title":"Increased frequency of diabetes mellitus in patients with Huntington\u2019s chorea","volume":"1","author":"Podolsky","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2006.09.016_bib64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.brainres.2004.10.030","article-title":"Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington\u2019s disease","volume":"1031","author":"Reynolds","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2006.09.016_bib65","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1111\/j.1460-9568.2004.03783.x","article-title":"Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington\u2019s disease mutation","volume":"20","author":"Ribchester","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2006.09.016_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","article-title":"The therapeutic role of creatine in Huntington\u2019s disease","volume":"108","author":"Ryu","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.nbd.2006.09.016_bib67","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/mds.20373","article-title":"Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington\u2019s disease","volume":"20","author":"Saft","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2006.09.016_bib68","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/WNL.53.4.806","article-title":"Clinical correlation of striatal 1H MRS changes in Huntington\u2019s disease","volume":"53","author":"Sanchez-Pernaute","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib69","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","article-title":"Formation of polyglutamine inclusions in non-CNS tissue","volume":"8","author":"Sathasivam","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib70","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/13518","article-title":"Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2006.09.016_bib71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0005-2728(98)00164-9","article-title":"Mitochondrial involvement in Parkinson\u2019s disease, Huntington\u2019s disease, hereditary spastic paraplegia and Friedreich\u2019s ataxia","volume":"1410","author":"Schapira","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2006.09.016_bib72","first-page":"293","article-title":"Assessment of in vitro and in vivo mitochondrial function in Friedreich\u2019s ataxia and Huntington\u2019s disease","volume":"277","author":"Schapira","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2006.09.016_bib73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s00247-004-1159-y","article-title":"MR imaging and spectroscopy in juvenile Huntington disease","volume":"34","author":"Schapiro","year":"2004","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.nbd.2006.09.016_bib74","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","article-title":"Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington\u2019s disease","volume":"17","author":"Schiefer","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2006.09.016_bib75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington\u2019s disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2006.09.016_bib76","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1093\/hmg\/ddi319","article-title":"HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism","volume":"14","author":"Seong","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib77","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archneur.56.10.1248","article-title":"Sympathetic skin response and heart rate variability in patients with Huntington disease","volume":"56","author":"Sharma","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib78","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q(10) formulations in Huntington\u2019s disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2006.09.016_bib79","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/jmg.29.12.911","article-title":"Causes of death in patients with Huntington\u2019s disease and in unaffected first degree relatives","volume":"29","author":"Sorensen","year":"1992","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib80","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.mad.2005.09.010","article-title":"Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation","volume":"127","author":"Squitieri","year":"2006","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.nbd.2006.09.016_bib81","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cne.20680","article-title":"Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington\u2019s disease transgenic mice","volume":"490","author":"Stack","year":"2005","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib82","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington\u2019s disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2006.09.016_bib83","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2006.09.016_bib84","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/hmg\/ddi192","article-title":"Gene expression in Huntington\u2019s disease skeletal muscle: a potential biomarker","volume":"14","author":"Strand","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib85","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng1193-259","article-title":"Widespread expression of the human and rat Huntington\u2019s disease gene in brain and nonneural tissues","volume":"5","author":"Strong","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.nbd.2006.09.016_bib86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E","article-title":"Biochemical abnormalities and excitotoxicity in Huntington\u2019s disease brain","volume":"45","author":"Tabrizi","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib87","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K","article-title":"Mitochondrial dysfunction and free radical damage in the Huntington R6\/2 transgenic mouse","volume":"47","author":"Tabrizi","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2006.09.016_bib88","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/01.WNL.0000070186.97463.A7","article-title":"Creatine therapy for Huntington\u2019s disease: clinical and MRS findings in a 1-year pilot study","volume":"61","author":"Tabrizi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib89","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1212\/01.WNL.0000160388.96242.77","article-title":"High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study","volume":"64","author":"Tabrizi","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib90","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nut.2003.10.007","article-title":"Assessment of the nutrition status of patients with Huntington\u2019s disease","volume":"20","author":"Trejo","year":"2004","journal-title":"Nutrition"},{"key":"10.1016\/j.nbd.2006.09.016_bib91","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/378403a0","article-title":"Polyglutamine expansion as a pathological epitope in Huntington\u2019s disease and four dominant cerebellar ataxias","volume":"378","author":"Trottier","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2006.09.016_bib92","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1021\/pr050244o","article-title":"Metabolic characterization of the R6\/2 transgenic mouse model of Huntington\u2019s disease by high-resolution MAS 1H NMR spectroscopy","volume":"5","author":"Tsang","year":"2006","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.nbd.2006.09.016_bib93","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/pr.54.4.619","article-title":"Protein nitration in cardiovascular diseases","volume":"54","author":"Turko","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.nbd.2006.09.016_bib94","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington\u2019s disease: a placebo-controlled pilot trial","volume":"61","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2006.09.016_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1009836822497","article-title":"Cardiac energy metabolism\u2014A historical perspective","volume":"4","author":"Vogt","year":"1999","journal-title":"Heart Failure Rev."},{"key":"10.1016\/j.nbd.2006.09.016_bib96","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0022-3565(24)39082-2","article-title":"Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice","volume":"294","author":"Weinstein","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2006.09.016_bib97","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996106002415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996106002415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T05:11:36Z","timestamp":1736658696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996106002415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0969996106002415"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2006.09.016","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}